Sunovion Pharmaceuticals reported positive late-stage test results for a new drug as both an add-on and standalone treatment for seizures associated with epilepsy.
The Marlborough-based company said using an 800 milligram or 1200 milligram dose of Aptiom as an add-on treatment reduced seizure frequency and virtually doubled the responder rates compared with a placebo. The U.S. Food and Drug Administration approved the drug for as an added treatment last month, and Sunovion plans to introduce it to the market in spring.
“There is a need for new therapies since approximately one-third of people with epilepsy continue to experience poor seizure control,” said Fred Grossman, the company’s senior vice president of clinical development and medical affairs.
As a standalone drug, the trials found that Aptiom did a better job controlling seizures in patients who are not well-served by the current treatment options.
Based on the study results, Grossman said Sunovion plans to seek approval of Aptiom as a standalone treatment.
